Document is current
Any future updates will be listed below
-
Authors
Talks, S. J. https://orcid.org/0000-0001-6126-6476
Stratton, I. https://orcid.org/0000-0003-1172-7865
Peto, T. https://orcid.org/0000-0001-6265-0381
Lotery, A. https://orcid.org/0000-0001-5541-4305
Chakravarthy, U. https://orcid.org/0000-0002-2606-3734
Eleftheriadis, H.
Izadi, S.
Dhingra, N.
Scanlon, P. https://orcid.org/0000-0001-8513-710X
,
Talks, James
Scanlon, Peter
Mohamed, Quresh
Lotery, Andrew
Kashani, Sharam
Georgas, Nasos
Jones, Colin
Gashut, Abdisattar
Santiago, Cynthia
Chhabra, Romi
Antcliff, Richard
Dhingra, Naren
Bailey, Clare
Chakravarthy, Usha
Peto, Tunde
Ghanchi, Faruque
Mcinerney, Linda
Natha, Salim
Khan, Rehna
Dias, Indra
Mukhrejee, Raj
Izadi, Shahrnaz
Tahir, Irfan
Eleftheriadis, Haralabos
- License Information
-
More Information
Article History
Received: 20 February 2021
Revised: 23 May 2021
Accepted: 2 June 2021
First Online: 9 July 2021
Competing interests
: SJT: Research and Advisory boards for Bayer; Novartis; Roche; Allergan; Alimera; IS: Consultant for Novo Nordisk; TP: Speaker and advisory board Bayer, Novartis, Roche; AL: None; UC: Chair of International trials sponsored by Bayer; HE: Research and Travel Bayer; SI: Research Bayer; travel Bayer and Novartis; ND: Research Novartis; Travel Novartis; Allergan; Bayer; Speaker Novartis; Advisory Board Novartis; PS: Research and audit grants from Allergan, Boehringer, Novartis, Bayer; Advisory Boards for Pfizer; Allergan; Roche; Boehringer and Bayer.
